Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance

This article was originally published in The Pink Sheet Daily

Executive Summary

Eli Lilly and Boehringer Ingelheim announced positive top-line data for a quartet of pivotal trials of their SGLT-2 candidate empagliflozin, while Lilly now will be going it alone on LY2605541, a long-acting insulin.

Advertisement

Related Content

Nothing To SAVOR For Bristol/AZ From Onglyza Results
Nothing To SAVOR For Bristol/AZ From Phase IV Results
Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission
In A Changing Diabetes Drug Market, Who Will Come Out On Top?
Boehringer’s Smith Discusses The Challenges Of Diabetes At ADA
New Long-Acting Insulin Offerings Could Derail Lantus Franchise
J&J’s Canagliflozin Positive Phase III Data In The Limelight At ADA
Dapagliflozin’s CV Profile Shines, But FDA Panel Review Falls On Cancer Concerns
Lilly/BI Eye Diabetes Leadership In Expansive Risk-Sharing Collaboration
Bristol Aims To Be First To Market With Novel Diabetes Drug Class

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074860

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel